Business Description
TOWA Pharmaceutical Co Ltd
NAICS : 325412
SIC : 2834
ISIN : JP3623150004
Share Class Description:
TWAPF: Ordinary SharesCompare
Compare
Traded in other countries / regions
4553.Japan6QC.GermanyTWAPF.USA IPO Date
2017-05-03Description
TOWA Pharmaceutical Co Ltd is a Japan based pharmaceutical company engaged in research and development, production, and marketing of generic drugs. It also provides drug consulting services for patients and their families and relatives. It organizes academic seminars for medical professionals and posts articles in journals. It participates in training for pharmacists. The company has three main plants in operation namely Osaka plant, Okayama plant, and Yamagata plant. Towa has offers more than 500 drugs to meet the diverse therapeutic requirements including lifestyle related diseases such as hypertension and diabetes, digestive system diseases, nervous system diseases and allergic diseases, vitamins and antibiotics.
Financial Strength
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.16 | |||||
| Equity-to-Asset | 0.36 | |||||
| Debt-to-Equity | 1.32 | |||||
| Debt-to-EBITDA | 10.58 | |||||
| Interest Coverage | 16.44 | |||||
| Piotroski F-Score | 5/9 | |||||
| Altman Z-Score | 1.86 | |||||
| Beneish M-Score | -2.37 | |||||
| WACC vs ROIC | ||||||
Growth Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 26.9 | |||||
| 3-Year EBITDA Growth Rate | -2.9 | |||||
| 3-Year EPS without NRI Growth Rate | -28.9 | |||||
| 3-Year Book Growth Rate | 9.4 | |||||
| Future 3-5Y Total Revenue Growth Rate | 7.54 |
Momentum Rank
1/10
| Name | Current | Vs Industry | Vs History |
|---|
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 2.77 | |||||
| Quick Ratio | 1.48 | |||||
| Cash Ratio | 0.4 | |||||
| Days Inventory | 226.86 | |||||
| Days Sales Outstanding | 80.53 | |||||
| Days Payable | 42.17 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Dividend Growth Rate | 10.9 | |||||
| Shareholder Yield % | -26.18 |
Profitability Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 34.66 | |||||
| Operating Margin % | 5.65 | |||||
| Net Margin % | 4.96 | |||||
| FCF Margin % | -12.45 | |||||
| ROE % | 8.21 | |||||
| ROA % | 3.04 | |||||
| ROIC % | 2.62 | |||||
| ROC (Joel Greenblatt) % | 7.77 | |||||
| ROCE % | 5.97 | |||||
| Years of Profitability over Past 10-Year | 10 |
GF Value Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 11.77 | |||||
| PE Ratio without NRI | 14.43 | |||||
| Shiller PE Ratio | 13.16 | |||||
| PEG Ratio | 1.78 | |||||
| PS Ratio | 0.58 | |||||
| PB Ratio | 0.93 | |||||
| Price-to-Tangible-Book | 1.39 | |||||
| Price-to-Operating-Cash-Flow | 54.29 | |||||
| EV-to-EBIT | 16.37 | |||||
| EV-to-EBITDA | 16.37 | |||||
| EV-to-Revenue | 1.28 | |||||
| EV-to-FCF | -10.87 | |||||
| Price-to-Projected-FCF | 1.32 | |||||
| Price-to-DCF (Earnings Based) | 1.11 | |||||
| Price-to-Median-PS-Value | 0.54 | |||||
| Price-to-Graham-Number | 0.94 | |||||
| Earnings Yield (Greenblatt) % | 6.11 | |||||
| FCF Yield % | -20.22 | |||||
| Forward Rate of Return (Yacktman) % | 8.89 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with OTCPK:TWAPF
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
TOWA Pharmaceutical Co Ltd Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 1,678.646 | ||
| EPS (TTM) ($) | 1.663 | ||
| Beta | -0.23 | ||
| Volatility % | 1.1 | ||
| 14-Day RSI | 0 | ||
| 14-Day ATR ($) | 0 | ||
| 20-Day SMA ($) | 24.35 | ||
| 12-1 Month Momentum % | 0 | ||
| 52-Week Range ($) | 24.35 - 24.35 | ||
| Shares Outstanding (Mil) | 49.22 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 5 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
TOWA Pharmaceutical Co Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
TOWA Pharmaceutical Co Ltd Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
TOWA Pharmaceutical Co Ltd Frequently Asked Questions
What is TOWA Pharmaceutical Co Ltd(TWAPF)'s stock price today?
The current price of TWAPF is $24.35. The 52 week high of TWAPF is $24.35 and 52 week low is $24.35.
When is next earnings date of TOWA Pharmaceutical Co Ltd(TWAPF)?
The next earnings date of TOWA Pharmaceutical Co Ltd(TWAPF) is .
Does TOWA Pharmaceutical Co Ltd(TWAPF) pay dividends? If so, how much?
TOWA Pharmaceutical Co Ltd(TWAPF) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers